Beam Therapeutics
Yahoo Finance • 3 days ago
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.
John M. Evans, CEO of Beam Therapeutics(NASDAQ:BEAM), executed an open-market sale of 30,078 shares on April 1, 2026, valued at approximately $739,000 according to the SEC Form 4 filing. Transaction summary Metric Value Shares sold (dire... Full story
Yahoo Finance • 11 days ago
Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM
Cathie Wood’s ARK Invest funds have delivered mixed performance in the recent period, with ARK Space & Defense Innovation ETF (ARKX [https://seekingalpha.com/symbol/ARKX]) up 1.27% and ARK Autonomous Technology & Robotics ETF (ARKQ [https:... Full story
Yahoo Finance • 12 days ago
Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years
Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the stocks that could 10x over the next 5 years. On March 3, H.C. Wainwright reaffirmed its Buy rating and $80 price target on Beam Therapeutics Inc. (NASDAQ:BEAM). The rating follows Beam’s... Full story
Yahoo Finance • 13 days ago
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31 Patients with SCD Demonstrated Deep Resolution... Full story
Yahoo Finance • 13 days ago
10 Stocks That Could 10X Over the Next 5 Years
In this article, we will take a look at 10 Stocks That Could 10X Over the Next 5 Years. March appears to be finishing on a low note, with the S&P 500 dipping on March 30, pulled down by new rises in oil prices and a sharp decline in techn... Full story
Yahoo Finance • 20 days ago
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Beam logo Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up Corrected M-AAT Comprised... Full story
Yahoo Finance • 2 months ago
Genomics Stocks That Deserve a Place in Your Portfolio in 2026
An updated edition of the Jan. 6, 2026, article. Genomics is the comprehensive study of genomes—the complete set of deoxyribonucleic acid (DNA) within an organism. Rapid scientific progress in this field has intensified interest among pha... Full story
Yahoo Finance • 2 months ago
Walmart downgraded, Etsy upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Barclays upgraded Etsy (ETSY) to Overw... Full story
Yahoo Finance • 2 months ago
Here is Why Beam Therapeutics (BEAM) Appears so Attractive
Beam Therapeutics (NASDAQ:BEAM) is one of the 17 biotechnology stocks with more than 50% upside. On January 22, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Beam Therapeutics (NASDAQ:BEAM), with a price target of $80.... Full story
Yahoo Finance • 2 months ago
H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval
Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating and $80 price target for Beam Therapeutics Inc. (NASDAQ:BEAM) on January 15, citi... Full story
Yahoo Finance • 2 months ago
Cathie Wood buys $43 million of megacap tech stock
It’s been a rocky start to the year for Cathie Wood, the head of Ark Investment Management. As of Feb. 6, Wood’s flagship Ark Innovation ETF (ARKK) was down 9.58% year to date, while the S&P 500 gained 1.27%, as pressure mounted on growth... Full story
Yahoo Finance • 3 months ago
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene
Beam Therapeutics Inc. (NASDAQ:BEAM) is among the 12 Best Genomics Stocks to Invest In.Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? TheFly reported on December 2, 2025, that Beam Therapeutics Inc. (NASDAQ:BEAM) has... Full story
Yahoo Finance • 3 months ago
Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock?
Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The fund’s investor class returned 30.9% i... Full story
Yahoo Finance • 3 months ago
TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock
This article first appeared on GuruFocus. Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (NASDAQ:TSLA) and Rocket Lab (NASDAQ:RKLB). Selling activity focused o... Full story
Yahoo Finance • 3 months ago
Cathie Wood invests heavily in gene-editing companies, offloads $30 million worth Tesla stock
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting holdings in... Full story
Yahoo Finance • 4 months ago
BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy
Beam Therapeutics (NASDAQ:BEAM) is one of the most promising mid-cap healthcare stocks under $50. On December 9, H.C. Wainwright analyst Patrick Trucchio reaffirmed his bullish stance on Beam Therapeutics (NASDAQ:BEAM). He rated the stock... Full story
Yahoo Finance • 4 months ago
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of B... Full story
Yahoo Finance • 4 months ago
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Durable for up to 20 Months P... Full story
Yahoo Finance • 4 months ago
Wednesday Sector Leaders: Biotechnology, Trucking Stocks
In trading on Wednesday, biotechnology shares were relative leaders, up on the day by about 4.3%. Leading the group were shares of Capricor Therapeutics, up about 352.3% and shares of Beam Therapeutics up about 11.9% on the day. Also sho... Full story
Yahoo Finance • 5 months ago
Cathie Wood's Ark Invest weekly recap: bets on AI-driven biotech, buys dip in CRCL, sells IRDM, PINS
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s ARK Invest reported a mixed week of aggressive buying in AI, biotech, and digital-asset infrastructure names, while con... Full story
